PMID- 19644599
OWN - NLM
STAT- MEDLINE
DCOM- 20100106
LR  - 20151119
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 29
IP  - 3
DP  - 2009 Aug
TI  - [Patients with oral anticoagulation--bridging anticoagulation in the 
      perioperative phase].
PG  - 247-55
AB  - Oral anticoagulation with a vitamin K-antagonist requires special consideration 
      when surgery or interventional procedures are planned. This is mainly due to the 
      half life of vitamin K-antagonists and to the need for safe and effective 
      anticoagulation prior to and during surgery as well as in the postoperative 
      period. So far, the continuous infusion of unfractionated heparin (UFH) has been 
      the medication of choice to "bridge" patients to surgery. The use of low 
      molecular weight heparins (LMWH) has been prospectively investigated in this 
      setting and represents a safe alternative. The advantages of LMWH are the better 
      dose-response relationship and reduced need for monitoring. This facilitates the 
      bridging procedure to be started out of hospital, which may reduce hospital stay 
      and associated costs. Furthermore, the so-called bridging of patients with oral 
      anticoagulation prior to and during surgery reduces bleeding complications and 
      maintains a safe anticoagulation for patients at risk.
FAU - Koscielny, J
AU  - Koscielny J
AD  - Universitatsmedizin Berlin, Institut fur Transfusionsmedizin, Gerinnungsambulanz, 
      Campus Charite Mitte, Chariteplatz 1, 10117 Berlin. juergen.koscielny@charite.de
FAU - Ziemer, S
AU  - Ziemer S
FAU - von Heymann, C
AU  - von Heymann C
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Patienten unter oraler Antikoagulation--Perioperatives Bridging.
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Morpholines)
RN  - 0 (Thiophenes)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Factor Xa Inhibitors
MH  - Humans
MH  - *Intraoperative Period
MH  - Morpholines/therapeutic use
MH  - Rivaroxaban
MH  - Thiophenes/therapeutic use
EDAT- 2009/08/01 09:00
MHDA- 2010/01/07 06:00
CRDT- 2009/08/01 09:00
PHST- 2009/08/01 09:00 [entrez]
PHST- 2009/08/01 09:00 [pubmed]
PHST- 2010/01/07 06:00 [medline]
AID - 09030247 [pii]
PST - ppublish
SO  - Hamostaseologie. 2009 Aug;29(3):247-55.